The Human Variable 

Chronic, multisystem collapse following infectious, environmental, or immunological insult has become one of the defining biomedical failures of the twenty-first century. The Unified Network Collapse Theory (UNCT™) reframes ME/CFS, Long COVID, POTS, MCAS, autoimmune destabilization, and post-vaccination or post-surgical syndromes as diversified expressions of a single systems-failure mode: Neuro-Immune-Autonomic Network Collapse. This framework is supported by decades of frag

The Antiviral Pairing Logic framework synthesizes longitudinal field analysis across more than two hundred patient trajectories with in silico terrain modeling and real-world pharmacology. Durable response consistently follows three preconditions: immune stabilization to prevent cytokine rebound, mast cell and autonomic modulation before viral clearance, and energy and vascular repair after antigen reduction.

CYNAERA REPURPOSED™ accelerates drug discovery for infection-associated chronic conditions like Long COVID and ME/CFS. Using AI-driven terrain modeling, it cuts repurposing timelines from years to weeks—identifying multi-indication therapies, reducing cost by up to 90%, and advancing patient-ready treatments through intelligent simulation.

Remission in ME/CFS is often described as spontaneous, yet nothing about it is random. The illusion of rarity comes from measurement bias. We record symptoms, not trajectory. When patient data is plotted longitudinally rather than episodically, a clear pattern emerges. Remission occurs when the body’s internal feedback systems, immune, autonomic, and metabolic, temporarily synchronize

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.